TokenPost·
Crescent Biopharma Posts $37.7 Million Q3 Loss as R&D Costs Rise
The net loss widened from $24.607 million a year earlier, while the per-share loss narrowed to $0.90. Crescent had $289.4 million in cash at quarter-end.
More news
- Crypto BriefingCrypto industry aligns with CFTC as legislative hopes fade
- Crypto BriefingFed’s Goolsbee warns inflation worsening, pressures policy tightening
- Crypto BriefingTwenty One Capital posts $1.087 billion Q3 net income on Bitcoin gains
- Crypto BriefingCharles Hoskinson says Cardano’s roadmap is complete as ADA holders push back
- TokenPostU.S. Producer Prices Rose 6.5% Year Over Year in October, Below Forecast
- TokenPostMicrosoft 365 Outage Disrupts Government Agencies and Global Businesses